TISIDB

Summary
Symbol	ROS1
Name	ROS proto-oncogene 1 , receptor tyrosine kinase
Aliases	MCF3; ROS; c-ros-1; v-ros avian UR2 sarcoma virus oncogene homolog 1; v-ros UR2 sarcoma virus oncogene homol ......
Chromosomal Location	6q21-q22
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Cell membrane Single-pass type I membrane protein
Domain	PF00041 Fibronectin type III domain PF07714 Protein tyrosine kinase
Function	Orphan receptor tyrosine kinase (RTK) that plays a role in epithelial cell differentiation and regionalization of the proximal epididymal epithelium. May activate several downstream signaling pathways related to cell differentiation, proliferation, growth and survival including the PI3 kinase-mTOR signaling pathway. Mediates the phosphorylation of PTPN11, an activator of this pathway. May also phosphorylate and activate the transcription factor STAT3 to control anchorage-independent cell growth. Mediates the phosphorylation and the activation of VAV3, a guanine nucleotide exchange factor regulating cell morphology. May activate other downstream signaling proteins including AKT1, MAPK1, MAPK3, IRS1 and PLCG2.

> Gene Ontology [ TOP ]
Biological Process	GO:0002064 epithelial cell development GO:0002065 columnar/cuboidal epithelial cell differentiation GO:0002066 columnar/cuboidal epithelial cell development GO:0006817 phosphate ion transport GO:0006820 anion transport GO:0007283 spermatogenesis GO:0010966 regulation of phosphate transport GO:0015698 inorganic anion transport GO:0016049 cell growth GO:0018108 peptidyl-tyrosine phosphorylation GO:0018212 peptidyl-tyrosine modification GO:0031929 TOR signaling GO:0032006 regulation of TOR signaling GO:0038083 peptidyl-tyrosine autophosphorylation GO:0044070 regulation of anion transport GO:0046777 protein autophosphorylation GO:0048232 male gamete generation GO:0070371 ERK1 and ERK2 cascade GO:0070372 regulation of ERK1 and ERK2 cascade
Molecular Function	GO:0004713 protein tyrosine kinase activity GO:0004714 transmembrane receptor protein tyrosine kinase activity GO:0019199 transmembrane receptor protein kinase activity GO:0019902 phosphatase binding GO:0019903 protein phosphatase binding
Cellular Component	-

> KEGG and Reactome Pathway [ TOP ]
KEGG	-
Reactome	-

Summary
Symbol	ROS1
Name	ROS proto-oncogene 1 , receptor tyrosine kinase
Aliases	MCF3; ROS; c-ros-1; v-ros avian UR2 sarcoma virus oncogene homolog 1; v-ros UR2 sarcoma virus oncogene homol ......
Chromosomal Location	6q21-q22
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between ROS1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining

[ TOP ]

Literatures describing the relation between ROS1 and anti-tumor immunity in human cancer.

PMID	Cancer type	Relation to immunity	Evidence sentences
23072905	Leukemia	Inhibit immunity (NK cell function)	Malignant granulocytes from patients with BCR-ABL-positive CML expressed the oxygen radical-producing enzyme NOX, produced large amounts of ROS, and triggered extensive cell death in NK cells.
29672044	Colorectal Carcinoma	Inhibit immunity	Andrographolide Antagonizes TNF-α-Induced IL-8 via Inhibition of NADPH Oxidase/ROS/NF-κB and Src/MAPKs/AP-1 Axis in Human Colorectal Cancer HCT116 Cells.
29669207	melanoma	Inhibit immunity	The outcomes revealed that ROS-inducing ZnPP PM demonstrated specificity for the in vitro and in vivo targeting of macrophages, elevated the level of ROS, and lowered STAT3 expression in BM-TAMs.

Summary
Symbol	ROS1
Name	ROS proto-oncogene 1 , receptor tyrosine kinase
Aliases	MCF3; ROS; c-ros-1; v-ros avian UR2 sarcoma virus oncogene homolog 1; v-ros UR2 sarcoma virus oncogene homol ......
Chromosomal Location	6q21-q22
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of ROS1 in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	ROS1
Name	ROS proto-oncogene 1 , receptor tyrosine kinase
Aliases	MCF3; ROS; c-ros-1; v-ros avian UR2 sarcoma virus oncogene homolog 1; v-ros UR2 sarcoma virus oncogene homol ......
Chromosomal Location	6q21-q22
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of ROS1 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	-0.473	0.0752
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	-0.857	0.157
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	-0.198	0.66
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	-0.514	0.537
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0.14	0.93
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	-1.353	0.418
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	-0.074	0.93
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	-0.028	0.985
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	-0.056	0.974
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	0.996	0.228
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	2.211	0.0356
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	-1.135	0.00903

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of ROS1 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	7.1	5.9	1.2	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	10	0	10	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	7.1	-7.1	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	14.8	12.3	2.5	0.744
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	7.1	-7.1	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	14.8	13.6	1.2	1
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	28.6	29.4	-0.8	1
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	37.5	0	37.5	0.209
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	23.1	45.5	-22.4	0.39
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	11.1	0	11.1	0.36
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	0	0	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	25	0	25	0.364
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	18.4	11.1	7.3	0.503
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	18.2	15.4	2.8	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	18.8	7.1	11.7	0.602
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	7.7	-7.7	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	8.3	-8.3	1

Summary
Symbol	ROS1
Name	ROS proto-oncogene 1 , receptor tyrosine kinase
Aliases	MCF3; ROS; c-ros-1; v-ros avian UR2 sarcoma virus oncogene homolog 1; v-ros UR2 sarcoma virus oncogene homol ......
Chromosomal Location	6q21-q22
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of ROS1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	ROS1
Name	ROS proto-oncogene 1 , receptor tyrosine kinase
Aliases	MCF3; ROS; c-ros-1; v-ros avian UR2 sarcoma virus oncogene homolog 1; v-ros UR2 sarcoma virus oncogene homol ......
Chromosomal Location	6q21-q22
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of ROS1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by ROS1. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	ROS1
Name	ROS proto-oncogene 1 , receptor tyrosine kinase
Aliases	MCF3; ROS; c-ros-1; v-ros avian UR2 sarcoma virus oncogene homolog 1; v-ros UR2 sarcoma virus oncogene homol ......
Chromosomal Location	6q21-q22
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of ROS1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	ROS1
Name	ROS proto-oncogene 1 , receptor tyrosine kinase
Aliases	MCF3; ROS; c-ros-1; v-ros avian UR2 sarcoma virus oncogene homolog 1; v-ros UR2 sarcoma virus oncogene homol ......
Chromosomal Location	6q21-q22
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of ROS1 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	ROS1
Name	ROS proto-oncogene 1 , receptor tyrosine kinase
Aliases	MCF3; ROS; c-ros-1; v-ros avian UR2 sarcoma virus oncogene homolog 1; v-ros UR2 sarcoma virus oncogene homol ......
Chromosomal Location	6q21-q22
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between ROS1 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	ROS1
Name	ROS proto-oncogene 1 , receptor tyrosine kinase
Aliases	MCF3; ROS; c-ros-1; v-ros avian UR2 sarcoma virus oncogene homolog 1; v-ros UR2 sarcoma virus oncogene homol ......
Chromosomal Location	6q21-q22
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting ROS1 collected from DrugBank database.

> Drugs from DrugBank database [ TOP ]
There is no record.

Browse ROS1